This page summarizes information about the clinical trials that support investigation of both approved and experimental medicines. This information includes information about the interventions and their sponsoring organizations. Note that these data are derived from ClinicalTrials.gov, with information corrected and disambiguated to convey more accurate detail about these trials. Phase 4 trials are currently excluded on this page by default, as this data will be analyzed separately at a later date.
Trials with Experimental APIs
Top 5 (by most trials)
bupivacaine (623) autologous hematopoietic stem cells (607) camrelizumab (430) tegafur (414) platelet-rich plasma (370)Trials with Approved APIs
Top 5 (by most trials)
paclitaxel (3570) cyclophosphamide (3425) cisplatin (3138) carboplatin (2684) gemcitabine (2458)Trials with Unapproved APIs
Top 5 (by most trials)
melatonin (321) red blood cells (77) platelets (47) benzocaine (36) salicylic acid (36)APIs in Phase 1
Top 5 (by most trials)
paclitaxel (984) cyclophosphamide (982) pembrolizumab (689) gemcitabine (687) carboplatin (671)APIs in Phase 2
Top 5 (by most trials)
paclitaxel (2796) cyclophosphamide (2560) cisplatin (2535) carboplatin (2161) gemcitabine (1916)APIs in Phase 3
Top 5 (by most trials)
cisplatin (877) cyclophosphamide (743) paclitaxel (735) fluorouracil (649) carboplatin (624)Phase 1 Sponsors
Top 5 (by most trials)
National Cancer Institute (NCI) (3403) Pfizer (1501) GlaxoSmithKline (1302) AstraZeneca (1102) National Institute of Allergy and Infectious Diseases (NIAID) (1046)Phase 2 Sponsors
Top 5 (by most trials)
National Cancer Institute (NCI) (5291) Harvard University (1581) University of Texas at Houston (1561) Novartis (1517) Merck (1235)Phase 3 Sponsors
Top 5 (by most trials)
Novartis (1204) Merck (1147) GlaxoSmithKline (1032) Pfizer (1013) National Cancer Institute (NCI) (959)Note: CRO, Devices and Generics organizations are excluded here.
